Compounds > gemcitabine
Page last updated: 2024-08-24

gemcitabine and osi 027

gemcitabine has been researched along with osi 027 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Bai, X; Chen, BW; Chen, W; Hu, L; Liang, C; Liang, T; Shen, J; Wen, L; Xue, F; Zhi, X; Zhou, Y1
Chen, B; Tang, JY; Tang, QH; Wang, XJ; Xu, M; Xu, MZ; Zhang, H1

Other Studies

3 other study(ies) available for gemcitabine and osi 027

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
    Oncotarget, 2015, Sep-22, Volume: 6, Issue:28

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Inhibitory Concentration 50; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice, Inbred BALB C; Mice, Nude; Multiprotein Complexes; Pancreatic Neoplasms; Protein Kinase Inhibitors; RNA Interference; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Transfection; Triazines; Tumor Burden; Xenograft Model Antitumor Assays

2015
The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.
    DNA and cell biology, 2015, Volume: 34, Issue:10

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Imidazoles; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Membrane Proteins; Mice, SCID; Multiprotein Complexes; Pancreatic Neoplasms; TOR Serine-Threonine Kinases; Triazines; Xenograft Model Antitumor Assays

2015